New treatments based on biological molecules like RNA give scientists unprecedented control over how cells function. But delivering those drugs to the right tissues remains one of the biggest obstacles to turning these promising yet fragile molecules into powerful new treatments.

Now Gensaic, founded by Lavi Erisson MBA ’19; Uyanga Tsedev SM ’15, PhD ’21; and Jonathan Hsu PhD ’22, is building an artificial intelligence-powered discovery engine to develop protein shuttles that can deliver therapeutic molecules like RNA to specific tissues and cells in the body. The company is using its platform to create advanced treatments for metabolic diseases and other conditions. It is also developing treatments in partnership with Novo Nordisk and exploring additional collaborations to amplify the speed and scale of its impact.